Raffaella Giavazzi
C.V.

  1. Buccione R., Baldassarre M., Trapani V., Catalano C., Pompeo A., Brancaccio A., Giavazzi R., Luini A., Corda D.: Glycerophosphoinositols inhibit the ability of tumour cells to invade the extracellular matrix. E. Journal of Cancer 41:470-76, 2005.

  2. Taraboletti G., Micheletti G., Dossi R., Borsotti P., Martinelli M., Fiordaliso F.: Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies. Clinical Cancer Res. 11(7):2720-26, 2005.

  3. Rybak J.N., Ettorre A., Kaissling B., Giavazzi R., Neri D., Elia G.: In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nature Methods 2(4):291-98, 2005.

  4. J. Golay, N. Di Gaetano, A. Amico, E. Cittera, A. M. Barbui, R. Giavazzi, A. Biondi, A. Rambaldi, M. Introna. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity aginst CD33+ acute lymphoblastic leukaemias in vitro and in vivo. Br. J. Haematol. 128:310-17, 2005.

  5. Füzéry A.K., Mihala N., Szabó P., Perczel A., Giavazzi R., Süli-Vargha H.: Solution state conformation and degradation of cyclopeptides containing an NGR motif. J. Pept. Sci. 11(1):53-9, 2005.

  6. Manenti L., Riccardi E., Marchini S., Naumova E., Floriani I., Garofalo A., Dossi R., Marrrazzo E., Ribatti D., Scanziani E., Bani M.R., Belotti D., Broggini M., Giavazzi R.: Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol. Cancer Ther. 4(5):715-25, 2005.

  7. Taraboletti G., D’Ascenzo S., Giusti I., Marchetti D., Borsotti P., Millimaggi D., Giavazzi R., Pavan A., Dolo V.: Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH1. Neoplasia 8(2):96-103, 2006.

  8. Naumova E., Ubezio P., Garofalo A., Borsotti P., Cassis L., Riccardi E., Scanziani E., Eccles S.A., Bani M.R., Giavazzi R.: The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin. Cancer Research 12(6):1839-49, 2006.

  9. Moreno M., Sani M., Raos G., Meille S. V., Belotti D., Giavazzi R., Bellosta S., Volonterio A., Zanda M. Stereochemically pure a-trifluoromethyl-malic hydroxamates: synthesis and evaluation as inhibitors of matrix metalloproteinases. Tetrahedron 62:10171-10181, 2006.

  10. Kruczynski A., Poli M., Dossi R., Chazottes E., Berrichon G., Ricome C., Giavazzi R., Hill B.T., Taraboletti G.: Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. E. Journal of Cancer 42:2821-32, 2006.

  11. Martinelli M, Bonezzi K, Riccardi E, Kuhn E, Frapolli R, Zucchetti M, Ryan AJ, Taraboletti G, Giavazzi R. Sequence dependent antitumor efficacy of the vascular distrupting agent ZD6126 in combination with paclitaxel. British Journal of Cancer 97(7):888-94, 2007.

  12. Giavazzi R., Bani M.R., Taraboletti G. Tumor-host interaction in the optimization of paclitaxel based combination therapies with vascular targeting compounds. Cancer Metastasis Reviews, 26:481-88, 2007.

  13. Giavazzi R., Taraboletti G. Targeting the tumor vasculature – Strategies for combination therapy. Medicina (Buenos Aires) 67:35-40, 2007.

  14. Margosio B., Rusnati M., Bonezzi K., Cordes B.l. A., Annis D.S., Urbinati C., Giavazzi R., Presta M., Ribatti D., Mosher D.F., Taraboletti G. Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. The International Journal of Biochemistry & Cell Biology 40:700-09, 2008.

  15. Belotti D., Calcagno C., Garofalo A., Caronia D., Riccardi E., Giavazzi R., Taraboletti G. Vascular Endothelial Growth Factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Molecular Cancer Research 6(4):525-34, 2008.

  16. Valentini G., D’Andrea C., Ferrari F., Pifferi A., Cobeddu R., Martinelli M., Natoli C., Ubezio P., Giavazzi R. In-vivo measurement of vascular modulation in experimental tumors using a fluorescent contrast agent. Photochemistry and Photobiology 84(5):1249-56, 2008.

  17. Ghilardi C., Chiorino G., Dossi R., Nagy Z., Giavazzi R., Bani M.R. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 30(9), 201, 2008.

  18. Naldini A., Filippi I., Ardinghi C., Silini A., Giavazzi R., Carraro F. Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. European Journal of Cancer 45(3):454-60, 2009.  

  19. Rösli C., Borgia B., Schliemann C., Gunther M., Wunderli-Allenspach H., Giavazzi R., Neri D. Comparative analysis of the membrane protome of closely related metastatic and non-metastatic tumor cells. Cancer Research 69(13):5406-14, 2009.

  20. Cesca M., Frapolli R., Berndt A., Scarlato V., Richter P., Kosmehl H., D’Inclaci M., Ryan A.J., Giavazzi R. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia 11(11):1155-64, 2009.

  21. Bonezzi K., Taraboletti G., Borsotti P., Bellina F., Rossi R., Giavazzi R. Vascular disrupting activity of tubulin-binding 1,5-Diaryl-1H-imidazoles. Journal of Medical Chemistry 52:7906-10, 2009.

  22. Coltrini D., Ronca R., Belleri M., Zardi L., Indraccolo S., Scarlato V., Giavazzi R., Presta M. Impact of VEGF-dependent tumor micro-environment on EDB fibronectin expression by subcutaneous human tumor xenografts in nude mice. The Journal of Pathology 219:455-62, 2009.

  23. Borgia B., Rösli C., Fugmann T., Schliemann C., Cesca M., Neri D., Giavazzi R. A proteomic approach for the identification of vascular markers of liver metastasis. Cancer Research 70(1):309-18, 2010.

  24. Silini A., Ghilardi C., Ardinghi C., Bernasconi S., Oliva P., Carraro F., Naldini A., Bani M.R., Giavazzi R. Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clinical & Experimental Metastasis 27(1):43-53, 2010.

  25. Colombo G., Margosio B., Ragona L., Neves M., Bonifacio S., Annis D.S., Stravalaci M., Tomaselli S., Giavazzi R., Rusnati M., Presta M., Zetta L., Mosher D.F., Ribatti D., Gobbi M., Taraboletti G. Non-peptidic thrombospondin-1-mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. Journal of Biological Chemistry 285(12):8733-42, 2010.

  26. Berndt A., Köllner R., Richter P., Franz M., Voigt A., Berndt A., Borsi L., Giavazzi R., Neri D., Kosmehl H. A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochemistry and Cell Biology 133:467-75, 2010.

  27. Naldini A., Filippi I., Miglietta D., Moschetta M., Giavazzi R., Carraro F. Interleukin-1b regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1α. European Journal of Cancer 46:3400-08, 2010.

  28. Moretti R.M., Mai S., Montagnani Marelli M., Bani MR., Ghilardi C., Giavazzi R., Taylor D.M., Martini P.G.V., Limonta P. Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. Endocrinology 151(10):4643-53, 2010.

  29. Frey K., Schliemann C., Schwager K., Giavazzi R., Johannsen M., Neri D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. The Journal of Urology 184(6):2540-8, 2010.

  30. Bello E., Colella G.,  Scarlato V., Oliva P., Berndt A., Valbusa G., Colombo S., D’Incalci M., Cavalletti E., Giavazzi R., Damia G., Camboni G. E-3810 a new, potent and selective dual inhibitor of VEGFR and FGFR with antitumor activity in different xenograft tumor models. Cancer Research, in press.

  31. Ruffini F., Failla C. M., Orecchia A., Bani M.R., Dorio A.S., Fortes C., Zambruno G., Graziani G., Giavazzi R., D’Atri S., Lacal P.M.Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumor progression. British Journal of Dermatology, in press.

  32. Moschetta M., Cesca M., Pretto F., Giavazzi R.: Angiogenesis Inhibitors: Implications for combination with conventional therapies. Current Pharmaceutical Design. In press.